U.S. FDA Accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed And Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio, Inc. (NASDAQ:TSVT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the companies' supplemental Biologics License